2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119918
    Cycrimine 77-39-4 ≥98.0%
    Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder.
    Cycrimine
  • HY-120149
    Inotodiol 35963-37-2 98.29%
    Inotodiol activates p53 signaling pathway, inhibits MMP-2/9, and exhibits antitumor activity in cancer cell HeLa. Inotodiol inhibits the generation of ROS and exhibits antioxidant and neuroprotective effects. Inotodiol inhibits the activation of MAPK and NF-κB signaling pathway, and exhibits anti-inflammatory activity. Inotodiol inhibits TLR-4 mediated TNF-α production (IC50s in BMMC and BMDM is 0.7 μM and 3.0 μM), inhibits the degranulation in mast cell, exhibits anti-allergic activity. Inotodiol is orally active.
    Inotodiol
  • HY-120170
    BMS-466442 1598424-76-0 ≥98.0%
    BMS-466442 is a potent and selective inhibitor of asc-1 (alanine serine cysteine transporter-1), with an IC50 of 11 nM. BMS-466442 inhibits [3H] D-serine uptake into rat brain synaptosomes, with an IC50 of 400 nM. BMS-466442 can be used for schizophrenia research.
    BMS-466442
  • HY-121186
    Bevantolol hydrochloride 42864-78-8 98.98%
    Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pKi values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca2+ antagonist.
    Bevantolol hydrochloride
  • HY-121301
    Amperozide 75558-90-6 98.75%
    Amperozide is an atypical antipsychotic that acts as an antagonist of the 5-HT2 receptor with a Ki value of 26 nM. Amperozide has a low affinity for D2 receptors.
    Amperozide
  • HY-121599
    CGP 36742 123690-78-8 ≥98.0%
    CGP 36742 (SGS-742) is an orally active and selective antagonist of GABAB receptor (IC50 = 36 µM). CGP 36742 is a blood-brain barrier (BBB) penetrant compound and improves cognitive performances. CGP 36742 can be used for depression study.
    CGP 36742
  • HY-121653
    Flesinoxan 98206-10-1 99.90%
    Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects.
    Flesinoxan
  • HY-121675
    2-Bromo-LSD 478-84-2
    2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation.
    2-Bromo-LSD
  • HY-121964
    cis-Piperidine-2,3-dicarboxylic acid 46026-75-9 ≥98.0%
    Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions.
    cis-Piperidine-2,3-dicarboxylic acid
  • HY-122376
    S-Bioallethrin 28434-00-6 98.16%
    S-Bioallethrin (D-Trans-Allethrin) is a pyrethroid insecticide. S-Bioallethrin disrupts nerve function by modifying the gating kinetics of transitions between the conducting and nonconducting states of voltage-gated sodium channels. S-Bioallethrin also causes inhibition of lymphocyte proliferation and induces histamine release from human basophils.
    S-Bioallethrin
  • HY-122672
    Adhesamine 462605-73-8 98.04%
    Adhesamine, dumbbell-shaped molecule, activates MAPK/FAK pathway. Adhesamine promotes adhesion and growth of mammalian cells. Adhesamine accelerates the differentiation and improves the survival of mice hippocampal neurons in primary culture.
    Adhesamine
  • HY-123856
    MY10 2204270-73-3 99.87%
    MY10 is a potent and orally active receptor protein tyrosine phosphatase (RPTPβ/ζ) inhibitor. MY10 reduces NF-κB p65 expression. MY10 activates tyrosine phosphorylation of c-Met. MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression. MY10 attenuates binge-like ethanol consumption and ethanol reward. MY10 can be used in the study of neurological and vascular diseases.
    MY10
  • HY-12388A
    N-Desmethyl clomipramine hydrochloride 29854-14-6 99.95%
    N-Desmethyl Clomipramine hydrochloride (Desmethylclomipramine hydrochloride) is a primary plasma N-desmethyl metabolite of Clomipramine. Clomipramine is a tricyclic antidepressant.
    N-Desmethyl clomipramine hydrochloride
  • HY-123936
    SR12343 2055101-86-3 ≥98.0%
    SR12343, an IKK/NF-κB inhibitor, is a NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic. SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, with an IC50 of 37.02 μM for TNF-α-mediated NF-κB activation. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 can be used for research of inflammatory and degenerative diseases.
    SR12343
  • HY-125039
    N-Acetyl lysyltyrosylcysteine amide 1287585-40-3 99.81%
    N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation.
    N-Acetyl lysyltyrosylcysteine amide
  • HY-125287
    (Rac)-Minzasolmin 1802518-63-3 99.87%
    (Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
    (Rac)-Minzasolmin
  • HY-125784
    Viloxazine hydrochloride 35604-67-2 ≥98.0%
    Viloxazine hydrochloride is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50=0.26 μM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 μM) and agonizes 5-HT2C receptors (EC50=32 μM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD).
    Viloxazine hydrochloride
  • HY-125904
    4-Hydroxyretinoic acid 66592-72-1
    4-Hydroxyretinoic acid (4-HRA) is a naturally occurring retinoid derivative with diverse biological effects. 4-Hydroxyretinoic acid is formed from retinol catalyzed by cytochrome P-450 isozyme(s), and is mainly metabolized by the liver in the body. 4-Hydroxyretinoic acid also serves as the substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. 4-Hydroxyretinoic acid regulates gene expression and cell differentiation via binding to nuclear receptor RAR (Retinoic Acid Receptor), and activates RARs and RXR-alpha, to induce cancer cell apoptosis. In addition, 4-Hydroxyretinoic acid is also involved in various physiological processes such as immune regulation, neuroprotection, and anti-oxidation.
    4-Hydroxyretinoic acid
  • HY-126415
    Magnesium Lithospermate B 122021-74-3 99.49%
    Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration.
    Magnesium Lithospermate B
  • HY-128855
    Talsaclidine 147025-53-4 ≥98.0%
    Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes. Talsaclidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Talsaclidine
Cat. No. Product Name / Synonyms Application Reactivity